| Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now! |
|
Join IQVIA Patient Suite experts Kevin Landells and Anthony Mikulaschek in this webinar as they explore the flexibility in choosing the right approach for integrating patient technology into your next trial. Whether you opt for an integrated solution or individual technology products, this webinar will guide you through the decision-making process to ensure you’re executing a patient technology strategy that fits your needs. 
|
|
Today’s Big NewsAug 26, 2024 |
|
Shape the Future of Life Sciences Entries for the Fierce Life Sciences Innovation Awards are coming to a close September 5th, 2024. Submit your entry & lead the charge in life sciences innovation. Enter now! 
|
|
| By Gabrielle Masson Just days after gene editor Tome Biosciences announced undisclosed operational cuts, a clearer picture is coming into focus as 131 employees are being laid off. |
|
|
|
By Nick Paul Taylor MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3 development. |
By Fraiser Kansteiner For Lykos Therapeutics and the company’s would-be MDMA-assisted therapy for post-traumatic stress disorder (PTSD), the hits just keep coming. Earlier this month, Lykos was hit by an FDA rejection, research paper retractions and layoffs. Now, the FDA is looking into studies sponsored by the company, The Wall Street Journal reports. |
Sponsored by InMed Pharmaceuticals New disease-modifying drugs, biological pathways and blood-based biomarker tests are among the rapid changes shaping the Alzheimer’s disease landscape |
|
Luminex MAP profiles
Ultrasensitive Simoa
Olink Target 48 Cytokine 
|
|
By Nick Paul Taylor Galapagos is coming under additional pressure from investors. Having built a 9.9% stake in Galapagos, EcoR1 Capital is now planning to talk to the Belgian biotech about its performance and the composition of its board. |
Sponsored by Bio-Rad Laboratories In this episode of The Top Line, sponsored by Bio-Rad, Dipika Gurnani delves into the challenges and solutions of quantifying HEK293 DNA in biotherapeutics, a field revolutionizing healthcare for over 350 million patients worldwide. |
By Darren Incorvaia Actinogen Medical’s hopes—and stock price—have rebounded slightly from earlier this month, when the Australian biotech announced its cortisol blocker had failed to improve attention and memory in patients with cognitive dysfunction and major depressive disorder. |
By Darren Incorvaia To digest large, infrequent feasts, a python's heart works overtime by increasing oxygen use, pumping more blood and swelling in size. This rapid response requires a heart that is soft and flexible, the opposite of the stiff and fibrous heart that is characteristic of many human cardiac diseases. |
By Gabrielle Masson,Darren Incorvaia,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Heather Landi After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. |
By Angus Liu Breast cancer treatments have evolved dramatically over the years, so Kyowa Kirin has decided to stop selling a decades-old drug in the U.S. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry. |
|
|---|
|
|
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| |
|
